AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Phase 3 Recruiting 135 enrolled Ottawa Heart Institute Research Corporation Canadian Institutes of Health Research (CIHR) · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.

Timeline

Start: 2021-06-28
Primary completion: 2027-03
Completion: 2029-03

Publications

Rheaume M, Aleksova N, Madsen JC, Benichou G. Chronic Rejection Series: Heart Cardiac Allograft Vasculopathy. Transplantation. 2026 Jan 1;110(1):e28-e41. doi: 10.1097/TP.0000000000005453. Epub 2025 Jul 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aspirin	Small molecule	81 mg	Oral
Comparator	Clopidogrel	Small molecule	75 mg	Oral

Indications

No indication recorded.